Neu Health, a precision neurology platform focused on Parkinson’s disease and dementia care, has been accepted into the six-month Global Incubator Programme (GIP): USA HealthTech – Medical Devices. The programme, which starts in September 2025 and runs through March 2026, is run by Innovate UK in partnership with Texas Medical Center Innovation and supported by the UK’s Department for Business & Trade.
According to the company, GIP will help Neu Health expand into the U.S. market by connecting the firm with Houston’s medical ecosystem, including hospitals, research institutions, and investor networks. Texas Medical Center treats about 10 million patients annually through its 21 member hospitals and research institutions.
Neu Health claims it recently earned FDA 510(k) clearance for its smartphone-based tool to measure resting tremor in Parkinson’s disease; this is said to be a fully phone-based system that requires no wearable or in-clinic hardware. The company is piloting its platform at U.S. health systems including Cedars-Sinai and Mass General Brigham, with additional U.S. expansion underway.
Built on more than a decade of research at Oxford University, the platform enables at-home assessments of speech, movement, and cognition, producing predictive scores and digital biomarkers. Neu Health said this aims to detect neurological decline earlier, reduce delays due to long neurology appointment wait times, and integrate into existing clinical workflows.
